Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02323191
Title A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

stomach cancer

urinary bladder cancer

Her2-receptor negative breast cancer

ovarian cancer

sarcoma

Therapies

Atezolizumab + Emactuzumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL

Facility Status City State Zip Country Details
Yale Cancer Center; Medical Oncology New Haven Connecticut 06520 United States Details
Massachusetts General Hospital. Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana Farber - Harvard Boston Massachusetts United States Details
Memorial Sloan-Kettering Cancer Center Breast & Imaging Center New York New York 10065 United States Details
Cliniques Universitaires St-Luc Bruxelles 1200 Belgium Details
Centre Leon Berard; Departement Oncologie Medicale Lyon 69373 France Details
Institut Claudius Regaud; Departement Oncologie Medicale Toulouse 31059 France Details
Institut Gustave Roussy; Departement Oncologie Medicale Villejuif 94805 France Details
Clinica Universitaria de Navarra; Servicio de Oncologia Pamplona Navarra 31008 Spain Details
Hospital del Mar; Servicio de Oncologia Barcelona 08003 Spain Details
Centro Integral Oncológico Clara Campal Ensayos Clínicos START Madrid 28050 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field